Cargando…
Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy
BACKGROUND: It is clear that the coordinated and reciprocal actions of kinases and phosphatases are fundamental in the regulation of development and growth of the malaria parasite. Protein Phosphatase type 1 is a key enzyme playing diverse and essential roles in cell survival. Its dephosphorylation...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735429/ https://www.ncbi.nlm.nih.gov/pubmed/23837822 http://dx.doi.org/10.1186/1741-7007-11-80 |
_version_ | 1782279644836265984 |
---|---|
author | Fréville, Aline Cailliau-Maggio, Katia Pierrot, Christine Tellier, Géraldine Kalamou, Hadidjatou Lafitte, Sophia Martoriati, Alain Pierce, Raymond J Bodart, Jean-François Khalife, Jamal |
author_facet | Fréville, Aline Cailliau-Maggio, Katia Pierrot, Christine Tellier, Géraldine Kalamou, Hadidjatou Lafitte, Sophia Martoriati, Alain Pierce, Raymond J Bodart, Jean-François Khalife, Jamal |
author_sort | Fréville, Aline |
collection | PubMed |
description | BACKGROUND: It is clear that the coordinated and reciprocal actions of kinases and phosphatases are fundamental in the regulation of development and growth of the malaria parasite. Protein Phosphatase type 1 is a key enzyme playing diverse and essential roles in cell survival. Its dephosphorylation activity/specificity is governed by the interaction of its catalytic subunit (PP1c) with regulatory proteins. Among these, inhibitor-2 (I2) is one of the most evolutionarily ancient PP1 regulators. In vivo studies in various organisms revealed a defect in chromosome segregation and cell cycle progression when the function of I2 is blocked. RESULTS: In this report, we present evidence that Plasmodium falciparum, the causative agent of the most deadly form of malaria, expresses a structural homolog of mammalian I2, named PfI2. Biochemical, in vitro and in vivo studies revealed that PfI2 binds PP1 and inhibits its activity. We further showed that the motifs (12)KTISW(16) and (102)HYNE(105) are critical for PfI2 inhibitory activity. Functional studies using the Xenopus oocyte model revealed that PfI2 is able to overcome the G2/M cell cycle checkpoint by inducing germinal vesicle breakdown. Genetic manipulations in P. falciparum suggest an essential role of PfI2 as no viable mutants with a disrupted PfI2 gene were detectable. Additionally, peptides derived from PfI2 and competing with RVxF binding sites in PP1 exhibit anti-plasmodial activity against blood stage parasites in vitro. CONCLUSIONS: Taken together, our data suggest that the PfI2 protein could play a role in the regulation of the P. falciparum cell cycle through its PfPP1 phosphatase regulatory activity. Structure-activity studies of this regulator led to the identification of peptides with anti-plasmodial activity against blood stage parasites in vitro suggesting that PP1c-regulator interactions could be a novel means to control malaria. |
format | Online Article Text |
id | pubmed-3735429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37354292013-08-07 Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy Fréville, Aline Cailliau-Maggio, Katia Pierrot, Christine Tellier, Géraldine Kalamou, Hadidjatou Lafitte, Sophia Martoriati, Alain Pierce, Raymond J Bodart, Jean-François Khalife, Jamal BMC Biol Research Article BACKGROUND: It is clear that the coordinated and reciprocal actions of kinases and phosphatases are fundamental in the regulation of development and growth of the malaria parasite. Protein Phosphatase type 1 is a key enzyme playing diverse and essential roles in cell survival. Its dephosphorylation activity/specificity is governed by the interaction of its catalytic subunit (PP1c) with regulatory proteins. Among these, inhibitor-2 (I2) is one of the most evolutionarily ancient PP1 regulators. In vivo studies in various organisms revealed a defect in chromosome segregation and cell cycle progression when the function of I2 is blocked. RESULTS: In this report, we present evidence that Plasmodium falciparum, the causative agent of the most deadly form of malaria, expresses a structural homolog of mammalian I2, named PfI2. Biochemical, in vitro and in vivo studies revealed that PfI2 binds PP1 and inhibits its activity. We further showed that the motifs (12)KTISW(16) and (102)HYNE(105) are critical for PfI2 inhibitory activity. Functional studies using the Xenopus oocyte model revealed that PfI2 is able to overcome the G2/M cell cycle checkpoint by inducing germinal vesicle breakdown. Genetic manipulations in P. falciparum suggest an essential role of PfI2 as no viable mutants with a disrupted PfI2 gene were detectable. Additionally, peptides derived from PfI2 and competing with RVxF binding sites in PP1 exhibit anti-plasmodial activity against blood stage parasites in vitro. CONCLUSIONS: Taken together, our data suggest that the PfI2 protein could play a role in the regulation of the P. falciparum cell cycle through its PfPP1 phosphatase regulatory activity. Structure-activity studies of this regulator led to the identification of peptides with anti-plasmodial activity against blood stage parasites in vitro suggesting that PP1c-regulator interactions could be a novel means to control malaria. BioMed Central 2013-07-09 /pmc/articles/PMC3735429/ /pubmed/23837822 http://dx.doi.org/10.1186/1741-7007-11-80 Text en Copyright © 2013 Frèville et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Fréville, Aline Cailliau-Maggio, Katia Pierrot, Christine Tellier, Géraldine Kalamou, Hadidjatou Lafitte, Sophia Martoriati, Alain Pierce, Raymond J Bodart, Jean-François Khalife, Jamal Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title | Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title_full | Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title_fullStr | Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title_full_unstemmed | Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title_short | Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy |
title_sort | plasmodium falciparum encodes a conserved active inhibitor-2 for protein phosphatase type 1: perspectives for novel anti-plasmodial therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735429/ https://www.ncbi.nlm.nih.gov/pubmed/23837822 http://dx.doi.org/10.1186/1741-7007-11-80 |
work_keys_str_mv | AT frevillealine plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT cailliaumaggiokatia plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT pierrotchristine plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT telliergeraldine plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT kalamouhadidjatou plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT lafittesophia plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT martoriatialain plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT pierceraymondj plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT bodartjeanfrancois plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy AT khalifejamal plasmodiumfalciparumencodesaconservedactiveinhibitor2forproteinphosphatasetype1perspectivesfornovelantiplasmodialtherapy |